Publications by authors named "I Antonyan"

Background: The standard of care for locoregional renal cell carcinoma is surgery, but many patients experience recurrence. The objective of the current study was to determine if adjuvant atezolizumab (vs placebo) delayed recurrence in patients with an increased risk of recurrence after resection.

Methods: IMmotion010 is a randomised, double-blind, multicentre, phase 3 trial conducted in 215 centres in 28 countries.

View Article and Find Full Text PDF

The study included 12 patients who underwent extracorporeal nephron-sparing surgery followed by autotransplantation of the kidney to the iliac region. A solitary kidney occurred in 7 (58.3%) cases, bilateral tumors in 2 (16.

View Article and Find Full Text PDF
Article Synopsis
  • - The paper examines the long-term outcomes of ureterocalicostomy (UC) in 37 patients, with a majority undergoing secondary procedures for conditions like hydronephrosis or kidney stones.
  • - Surgical resections were categorized by the thickness of kidney tissue removed, revealing that most had significant lower pole removals, and complications were mostly mild (Grade I-II) occurring in 37.8% of cases.
  • - Overall, 81.1% of patients achieved good results post-surgery, with the thickness of renal parenchyma under 10 mm identified as a key predictor for poorer outcomes.
View Article and Find Full Text PDF

In most cases RCC with venous extension is an indication for radical nephrectomy. However, in patients with imperative indications for nephron-sparing surgery a kidney resection with thrombectomy in rare situations is possible. We present a surgical technique for nephron-sparing surgery in patients with tumor spreading into the main renal vein.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "I Antonyan"

  • - I Antonyan's recent research focuses on surgical interventions and adjuvant therapies for renal cell carcinoma (RCC), particularly concerning methods to reduce recurrence risk post-surgery and improve patient outcomes.
  • - The article "Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010)" explores the efficacy of adjuvant immunotherapy in delaying recurrence in high-risk patients, indicating significant potential benefits.
  • - Additional studies by I Antonyan, including extracorporeal nephron-sparing surgery and ureterocalicostomy, highlight innovative surgical techniques and their long-term results, expanding the scope of treatment options for patients with complex cases of RCC.